Industries > Pharma > Global Erythropoietin Market Forecast 2017-2027

Global Erythropoietin Market Forecast 2017-2027

Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, Biosimilars, EPO API Manufacturing

PUBLISHED: 28 April 2017
PAGES: 164
PRODUCT CODE: PHA0187
SUBMARKET: Therapeutic Drugs

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA0187 Categories: , Tags: ,

The global erythropoietin market is expected to grow at a CAGR of 7.8% in the first half of the forecast period and CAGR of 4.8% in the second half of the forecast period. The market is estimated at $7.9bn in 2016 and $16.5bn in 2027.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 164-page report you will receive 84 tables and 93 figures – all unavailable elsewhere.

The 164-page report provides clear detailed insight into the global erythropoietin market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Global Erythropoietin Market forecasts from 2017-2027

• Revenue forecasts of global erythropoietin market, segmented by product type:
– Epoetin Alfa
– Epoetin Beta
– Darbepoetin Alfa
– Biosimilars
– Others

This section also discusses the leading drugs as well as SWOT analysis of each submarket.

• Revenue forecasts of global erythropoietin market, segmented by application:
– Anemia (Cancer and HIV Treatment)
– Kidney Disorders (ESRD and Dialysis)
– Others

• Revenue forecasts of global erythropoietin API manufacturing market, segmented by contract manufacturing and in-house manufacturing

• Erythropoietin Leading Regional Market forecasts from 2017-2027 covering North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.

Global Erythropoietin Market Forecast 2017-2027

Forecast for each regional market is further segmented by product type, application and country:
– US
– Canada
– UK
– Germany
– France
– Spain
– Italy
– Rest of Europe
– China
– Japan
– India
– Rest of Asia-Pacific
– Brazil
– Mexico
– Rest of Latin America
– Saudi Arabia
– South Africa
– Rest of Middle East and Africa

• Assessment of selected leading companies that hold major market shares in the erythropoietin market:
– Amgen
– Johnson & Johnson
– Roche
– Biocon
– 3SBio
– Pfizer
– Kyowa Hakko Kirin Co Ltd
– LG Life Sciences Limited
– Intas Pharmaceuticals Ltd
– Novartis AG

Visiongain’s study is intended for anyone requiring commercial analyses for the erythropoietin market. You find data, trends and predictions.

Buy our report today Global Erythropoietin Market Forecast 2017-2027: Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, Biosimilars, EPO API Manufacturing.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Erythropoietin Market Forecast 2017-2027

    Download sample pages

    Complete the form below to download your free sample pages for Global Erythropoietin Market Forecast 2017-2027

      Latest Pharma news

      Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

      The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

      18 April 2024

      READ

      Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

      The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

      17 April 2024

      READ

      Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

      The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

      12 April 2024

      READ

      Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034

      The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.

      11 April 2024

      READ